<?xml version="1.0" encoding="UTF-8"?>
<p id="par0030">On 8 April 2020 they had collected information on 115 candidate vaccine products at different stages of development. 78 of them have been confirmed to be active and this is not the case for 37 other candidates. The projects include a broad range of technological platforms, with traditional or new approaches. The majority are in exploratory or preclinical stages. However, 5 of the candidate products have already entered the clinical development phase:
 <list list-type="simple" id="lis0005">
  <list-item id="lsti0005">
   <label>•</label>
   <p id="par0035">
    <italic>mRNA-1273.</italic> ARNm vaccine that codifies protein S encapsulated in lipid nanoparticles (Moderna).
   </p>
  </list-item>
  <list-item id="lsti0010">
   <label>•</label>
   <p id="par0040">
    <italic>Ad5-nCoV.</italic> Type 5 adenovirus vector that expresses protein S (CanSino Biologicals).
   </p>
  </list-item>
  <list-item id="lsti0015">
   <label>•</label>
   <p id="par0045">
    <italic>INO-4800.</italic> DNA plasmid that codifies protein S administered by electroporation (Inovio Pharmaceutical).
   </p>
  </list-item>
  <list-item id="lsti0020">
   <label>•</label>
   <p id="par0050">
    <italic>LV-SMENP-DC.</italic> Modified dendritic cells with a lentiviral vector that include minigenes that express conserved structural protein domains and proteases (Shenzhen Geno-Immune Medical Institute).
   </p>
  </list-item>
  <list-item id="lsti0025">
   <label>•</label>
   <p id="par0055">
    <italic>Pathogen-specific aAPC.</italic> Antigen presenter cells modified with lentiviral vector (Shenzhen Geno-Immune Medical Institute).
   </p>
  </list-item>
 </list>
</p>
